Compare Datadog Inc (DDOG) vs Novo Nordisk A/S (NVO) Price & Performance

Datadog IncTrade

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Datadog Inc vs Novo Nordisk A/S — how do they compare? Datadog Inc trades at $247.1 (market cap $88.61B), while Novo Nordisk A/S trades at $46.28 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 2.3× Datadog Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Datadog Inc pays none. Which is the better fit depends on your goals.

	DDOG	NVO
Market Cap	$88.61B	$207.85B
Sector	Technology	Health
52-Week High	$288.15	$63.98
52-Week Low	$102.62	$35.29
Enterprise Value	$84.90B	$222.55B
Dividend Yield	—	3.81%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Datadog Inc

Datadog (DDOG) trades at $241.00, down 7.58% amid a bearish technical signal despite strong Q2 2026 earnings beats and raised full-year guidance. The stock shows elevated valuation ratios (P/E 493.56, P/S 22.83) but maintains robust revenue growth (36% YoY in Q2) and a high gross profit margin of 79.51%. Recent insider selling and mixed technical indicators contrast with an 83% analyst buy rating.

Outlook: Long-term growth driven by AI demand and net revenue retention above 120% supports upside to the $288.55 consensus target. Risks include valuation sensitivity, customer concentration, and execution pressure. The stock presents a growth opportunity with volatility near-term.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.

Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

DDOG

Fastly shares jump 21% on strong Q2 results and raised full-year outlook, hitting highest levels since early 2024.24/7 Wall Street · 2 days agoBullish Global X Cloud Computing ETF (CLOU) rated buy for strong growth beyond AI and resilient revenue streamsSeeking Alpha · 2 days agoBullish View details →

NVO

Novo Nordisk CEO says GLP-1 drugs for obesity have huge growth potential and economic benefits aheadFox Business · 7 hours agoBullish Novo Nordisk stays a Buy with strong obesity drug lead and improved 2026 outlook despite near-term challenges.Seeking Alpha · 10 hours agoBullish Novo Nordisk faces sell rating amid rising competition and operational challenges, with price target cut to $47.Alex Lavoie · 11 hours agoBearish View details →

About Datadog Inc

Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.